Prognosis and Management of Low-Risk Myelodysplastic Syndrome with Coronary Artery Disease

Prognostic Assessment

The five-year survival rate for a patient with low-risk myelodysplastic syndrome (MDS) and significant coronary artery disease is approximately 60-70%, with management requiring a balanced approach addressing both conditions 1, 2
Low-risk MDS patients have a median survival of 3-10 years, with a 5-year survival rate of approximately 68% 3
Factors that improve prognosis in low-risk MDS include relatively stable blood counts over time 4, absence of RBC transfusion dependence 1, 5, low percentage of bone marrow blasts 1, and absence of poor-risk cytogenetics 2

Comorbidities, particularly cardiovascular disease, are independent prognostic factors that can reduce overall survival in MDS patients 1, 2
A coronary calcium score of 1600 indicates severe coronary artery disease, which significantly impacts overall prognosis 6
A 60% LAD lesion with a fractional flow reserve (FFR) of 0.76 after adenosine indicates hemodynamically significant coronary stenosis requiring intervention 7

The American College of Cardiology recommends optimizing antiplatelet therapy while considering thrombocytopenia risk 5, 6
The National Comprehensive Cancer Network recommends regular monitoring of blood counts to assess disease stability 4
Erythropoiesis-stimulating agents (ESAs) should be considered if the patient develops symptomatic anemia, particularly with low serum erythropoietin levels 4, 3
Response rates to ESAs range from 40-60% in low-risk MDS patients 3

Regular blood count monitoring every 1-3 months to assess MDS stability is recommended 4, 1
Bone marrow examination is recommended if there is significant deterioration in blood counts 4
Cardiac follow-up with stress testing or imaging to monitor coronary disease is necessary 7
Assess for signs of disease progression in MDS, including increasing blast percentage or worsening cytopenias 1, 2